M&A
confidence high
sentiment positive
materiality 0.90
FibroGen sells China ops to AstraZeneca for ~$160M; cash runway to 2027
KYNTRA BIO, INC.
- Purchase price: $85M enterprise value plus net China cash (~$75M) for total ~$160M.
- Transaction expected to close by mid-2025, subject to China regulatory approval.
- Proceeds will repay ~$80M term loan to Morgan Stanley Tactical Value; cash runway extended into 2027.
- Upon close, AstraZeneca gets full roxadustat rights in China; FibroGen retains U.S. and ex-AstraZeneca markets.
- Senior VP China Operations Christine Chung will depart upon closing; Phase 2 trial of FG-3246 in mCRPC expected 2Q 2025.